What is des syndrome?

The

Diethylstilbestrol syndrome is a group of reproductive health problems recorded in women born mothers who have been prescribed desing in pregnancy. This synthetic estrogen has been used since the end of the thirties to 80. Scientists later realized that the daughters of des, as they are known, were more susceptible to certain reproductive health conditions due to their exposure to the drug during pregnancy. The use of des in pregnant women is no longer standard due to these health risks. They can also experience infertility and other problems related to the reproductive tract within the DES syndrome. Their incidence of breast cancer is higher than in the normal population. These abnormalities have not become easily obvious until the children born to mothers who took the des grew up, when the whole generation was already exposed to a drug.

In addition, women who used desing during pregnancy have a higher risk of breast cancer. They do not experience gynecological cancer associated with fetal exposure but must receiveRoutine evaluation for breast abnormalities to capture breast cancer soon. These complications were also reflected later, as it may take decades to develop breast cancer. As with some other cancer -causing substances, DES was not immediately associated with these problems, because epidemiologists had to assemble several pieces of puzzles to find a connection.

This problem of public health illustrates the complexity of conducting drug safety studies in pregnant women. The des syndrome did not appear until medicines have been used for decades and there was no way to anticipate des syndrome based on the original research that led to the drug approval. Following the complications of medicines after release of the open market drugs is an important part of drug safety that allows care providers to identify long -term complications as soon as possible.

Women born between approximately 1940 and 1980They can be threatened by the desord, depending on where they were born. Some nations reported the use of this drug earlier than others. In cases where there are concerns about desing des, the patient may need more extensive diagnostic scanning and evaluation than recommended for the general population. This may include the launch of breast cancer screening earlier in life and regularly receiving papers to identify early signs of cellular changes.